Free Trial

Cingulate (CING) News Today

Cingulate logo
$4.76 -0.22 (-4.42%)
As of 01/17/2025 04:00 PM Eastern
Cingulate (NASDAQ:CING) Upgraded at Roth Capital
Cingulate (NASDAQ:CING) Now Covered by Roth Mkm
Cingulate Inc Completes Key FDA Study for ADHD Drug
Final Study Completed for Cingulate’s Lead Asset CTx-1301
Cingulate completed final FDA-required study for CTx-1301 for ADHD
Cingulate completes financing transaction for net proceeds of $5M
Maxim Group Upgrades Cingulate (CING)
Cingulate upgraded to Buy from Hold at Maxim
CING: Third Quarter Results
Cingulate sees cash runway into 3Q25
Cingulate reports Q3 net loss $3.2M vs. $5.98M last year
Learning the art of letting go
Why conservatism is built into the brain
Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301
Get Cingulate News Delivered to You Automatically

Sign up to receive the latest news and ratings for CING and its competitors with MarketBeat's FREE daily newsletter.

CING Media Mentions By Week

CING Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CING
News Sentiment

0.00

0.48

Average
Medical
News Sentiment

CING News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CING Articles
This Week

0

3

CING Articles
Average Week

Get Cingulate News Delivered to You Automatically

Sign up to receive the latest news and ratings for CING and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:CING) was last updated on 1/21/2025 by MarketBeat.com Staff
From Our Partners